Drugs / 177Lu-PSMA-1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06059014 | Nov 2023 → Jul 2025 | clear cell renal carcinoma | Centre Leon Berard | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 177Lu-PSMA-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06059014 ↗ |
| Modality | Other / unclassified | “radionuclide therapy” NCT06059014 ↗ |
| Route | Intravenous | “intravenously (IV)” NCT06059014 ↗ |